Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

Johnson & Johnson Options to Acquire Sail Biomedicines for $2.58 Billion

August 2, 2026

Biotechnology

Johnson & Johnson entered into strategic agreements with Sail Biomedicines to collaborate on in vivo CAR-T therapies and secured an exclusive option to acquire Sail for $2.58 billion. The deal includes initial payments totaling $785 million (including a $465 million equity investment) and up to $140 million in additional development milestone payments, with the $2.58 billion payable if the option is exercised.

Johnson & Johnson to Acquire Firefly Bio for $1 Billion

June 8, 2026

Biotechnology

Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The deal is intended to expand Johnson & Johnson’s oncology pipeline using Firefly Bio’s proprietary Firelink degrader antibody conjugate platform, including preclinical candidates for KRAS-driven and other hard-to-treat solid tumors.

Jazz Pharmaceuticals Acquires Chimerix for About $935 Million

March 5, 2025

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix in an all-cash transaction valued at approximately $935 million (about $8.55 per share). The deal is expected to close in the second quarter of 2025, pending customary closing conditions, including tender of shares in a tender offer.

Johnson & Johnson to Acquire Proteologix, Inc.

May 16, 2024

Biotechnology

Johnson & Johnson entered into a definitive agreement to acquire privately held biotechnology company Proteologix for $850 million in cash, with potential additional milestone payments. The deal is expected to close mid-year 2024 subject to antitrust clearance and customary closing conditions, expanding J&J’s bispecific antibody pipeline for immune-mediated diseases including atopic dermatitis and asthma.

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.